Subclinical Atherosclerosis Risk Can Be Predicted in Female Patients With Systemic Lupus Erythematosus Using Metabolomic Signatures: An Observational Study

Cardiovascular disease (CVD) is a leading cause of death in women with systemic lupus erythematosus (SLE) due to accelerated atherosclerosis that is not predicted by established CVD risk scores. This study aimed to develop, validate, and test a female-focused predictive atherosclerosis risk signatur...

ver descrição completa

Detalhes bibliográficos
Autores: Woodridge, Laurel, Tektonidou, Maria G., Robinson, George A., Peng, Junjie, Coelewij, Leda, Martin-Gutierrez, Lucia, Chocano Navarro, Elvira, Griffin, Maura, Nicolaides, Andrew, Ciurtin, Coziana, Rahman, Anisur, Pineda-Torra, Inés, Jury, Elizabeth C.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/394869
Acesso em linha:http://hdl.handle.net/10261/394869
https://api.elsevier.com/content/abstract/scopus_id/105003658887
Access Level:acceso abierto
Palavra-chave:SLE
Cardiovascular disease risk
Female
Metabolomics
Subclinical atherosclerosis
Descrição
Resumo:Cardiovascular disease (CVD) is a leading cause of death in women with systemic lupus erythematosus (SLE) due to accelerated atherosclerosis that is not predicted by established CVD risk scores. This study aimed to develop, validate, and test a female-focused predictive atherosclerosis risk signature based on serum metabolites in patients with SLE.

Registos relacionados